NCT05076396: PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: All breast cancer patients are eligible for the dose escalation phase, but only breast cancer patients with a germline (hereditary) BRCA mutation are eligible for the expansion phase
Exclusions: For the expansion phase, patients with more than three prior chemotherapy lines for breast cancer – see trial for details on what qualifies as a line of therapy; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with history of leptomeningeal disease

Comments are closed.

Up ↑